Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells
Anlotinib has been demonstrated its anti-tumor efficacy on non-small cell lung cancer (NSCLC) in clinical trials at 3rd line. However, anlotinib resistance occurs during its administration, and the underlying mechanism is still unclear.
Anlotinib resistant lung cancer cell line NCI-H1975 was established in vitro. Toxicologic effects undergoing anlotinib stress were observed upon NCI-H1975 cells and anlotinib resistant NCI-H1975 cells, respectively. Transcriptome profiling was performed to screen anlotinib resistance-associated genes between NCI-H1975 cells and anlotinib resistant NCI-H1975 cells. Functional assays were performed to examine the correlations between CXCL2 gene expression and anlotinib resistance.
We found anlotinib inhibits cell proliferation and cell viability in NCI-1975 cells, whereas it attenuates these activities in anlotinib resistant NCI-H1975 cells. Transcriptome profiling analysis identified 769 anlotinib-responsive genes enriched in the biological processes of microtubule-based process, cytoskeleton organization, and wound healing. Furthermore, we found 127 genes are associated with anlotinib resistance. In particular, we demonstrated that CXCL2 contributes to anlotinib resistance in NCI-H1975 cells.
This study suggested that CXCL2 is involved in anlotinib resistance in NCI-H1975 cells and provided an insight for understanding the resistant mechanism of anlotinib.
KeywordsAnlotinib Drug resistance CXCL2 Non-Small Cell Lung Cancer Transcriptome
C-X-C Motif Chemokine Ligand 2
Database for Annotation, Visualization and Integrated Discovery
Epidermal Growth Factor Receptor
Kyoto Encyclopedia of Genes and Genomes
National Comprehensive Cancer Network
Non-Small Cell Lung Cancer
Platelet-derived Growth Factor Receptor; FGFR
Fibroblast Growth Factor Receptor
Progression Free Survival
Reads per Kilo-base of Transcript per Million
Tyrosine Kinase Receptor Inhibitor
Vascular Endothelial Growth Factor Receptor 2
Lung cancer is one of the most malignant cancers, and the non-small cell lung cancer (NSCLC) accounts for 80–85% of all lung cancer cases [1, 2, 3]. According to National Comprehensive Cancer Network (NCCN) guideline, the regimes of 1st line and 2nd line therapy bring great survival benefit for NSCLC patients, while the regimes of 3rd line therapy have not been available so far [4, 5]. Anlotinib is an oral multi-targeted tyrosine kinase receptor inhibitor (TKI) . Previous studies demonstrated that anlotinib inhibits proliferation and induces apoptosis of tumor cells via selectively inhibiting VEGFR (2/3), FGFR (1–4), and PDGFR (α/β) [7, 8]. Clinical trials have indicated anlotinib prolongs progression free survival (PFS) and overall survival (OS) of NSCLC patients significantly at 3rd line [9, 10, 11]. However, the median PFS of 5.37 months suggests anlotinib resistance occurred at later stage.
Investigating the mechanisms of anti-tumor drug resistance will improve the therapeutic efficiency or promote novel agent discovery. Previous studies have showed the NSCLC patients harboring EGFR positive mutations (L858R or 19 Del) acquired drug resistance with median PFS of about 10 months when they were treated with the first generation TKIs (Gefitinib, Erlotinib and Icotinib) [12, 13, 14, 15]. More studies revealed that T790 M mutation and other gene over-expression account for the majority [12, 16, 17]. Based on these findings, scientists have found the 3rd generation TKI AZD9291 is effectively for the patients harboring T790 M mutation [18, 19, 20]. Investigating the resistant mechanism of anlotinib, a 3rd line TKI, will be helpful to formulate the anlotinib-based therapeutic regime, and prolong PFS of NSCLC patients. In this study, we generated anlotinib resistant human lung cancer cell line NCI-H1975 in vitro, performed transcriptome analysis in NCI-H1975 cells and anlotinib resistant NCI-H1975 cells, and their anlotinib-treated counterpart with the aim to understand the mechanisms of anlotinib resistance.
Materials and methods
Human NSCLC cell line NCI-H1975 was purchased from ATCC (the global bioresource center, https://www.atcc.org/). TransDetect PCR Mycoplasma Detection Kit (TransGen, China) was used for excluding mycoplasma contamination. Cells were cultured in the mixed medium of 90% RPMI 1640 (Gibco, USA), 10% FBS (Gibco, USA), and 0.1 mg/ml streptomycin and 100 U/ml penicillin. All cells were incubated at 37°C in a humidified incubator containing 5% CO2.
Generation of anlotinib resistant NCI-H1975
Anlotinib resistant NCI-H1975 was generated as previous reported [21, 22]. Briefly, 100 mg/ml ENU (sigma, USA) was exposed to totally 107 NCI-H1975 cells for 24 h. And then, gradient concentration of anlotinib treatment was performed to induce anlotinib resistant NCI-H1975 cells. At first five days, NCI-H1975 cells were exposed to anlotinib (4 μg/ml) and the medium was changed every day. Then anlotinib (6 μg/ml, 8 μg/ml, 10 μg/ml and 12 μg/ml) treatments were performed in the next two months. The last cells (about 100 cells) showed viability when exposing to anlotinib (12 μg/ml). Lastly, after about one month’s proliferation, the anlotinib resistant NCI-H1975 cells were used to functional assays.
Cell number and cell viability analysis
For evaluating the effects of anlotinib on cell growth, 105 NCI-H1975 cells were seeded in each well of 6-well plates, and then exposed to anlotinib (8 μg/ml) for 24 h. Cell number changes in NCI-H1975 cells were observed with a phase-contrast microscope (Nikon, Japan). 103 cells were seeded in 96-well plates and treated with anlotinib (8 μg/ml) for 24 h. Cell viability was determined using Cell Counting Kit 8 (CCK8, Dojindo, Japan) by spectrophotometric plate reader (Omega Bio-Tek, USA).
RNA-seq library construction
RNA-seq library was performed as previous described [23, 24, 25]. Briefly, NCI-H1975 cells and anlotinib resistant NCI-H1975 cells were exposed to anlotinib (8 μg/ml) for 24 h. Total RNA was extracted by Trizol (Life Technologies, USA) according to the manufacturer’s protocol. mRNA was isolated from total RNA using Oligotex mRNA Mini Kit (Qiagen, Germany). Totally, 100 ng mRNA was used for library construction. After cDNA reverse-transcription, end repair and ligation, the original library was amplified 10–12 cycles in a thermal cycler using Q5 DNA Polymerase (NEB, USA). Lastly, the PCR products were performed by standard pair-end sequencing with 150 bp reads with Illumina Next500 (Illumina, USA). Raw data are available in the EMBL database under accession number E-MTAB-5997 and E-MTAB-7068.
RNA-seq data processing
The sequencing quality of raw data was examined by FastQC software (Version 0.11.6). Qualified tags were mapped to reference genome (hg 38) by Tophat . Cufflinks was used to characterize the differential transcription pattern . Reads per kilo-base of transcript per million (RPKM) was used for detecting gene expression level. We performed differential gene expression analysis with RNA-seq data sets derived from NCI-H1975 and anlotinib-treated NCI-H1975, yielding 769 anlotinib-responsive genes. For the RNA-seq data sets generated with anlotinib resistant NCI-H1975 and anlotinib-treated anlotinib resistant NCI-H1975, we firstly removed genes whose transcription is modulated by anlotinib (RPKM in anlotinib resistant NCI-H1975 /RPKM in anlotinib-treated anlotinib resistant NCI-H1975 > 1), the resulting genes were intersected with anlotinib responsive genes and the cancer gene pool (http://www.bushmanlab.org/links/genelists), yielding 127 genes that are associated with Anlotinib resistance.
Functional annotation and pathway analysis
According to our previous studies [23, 25, 27], functional annotation and pathway analysis were performed by public bioinformatics resource platforms named Database for Annotation, Visualization and Integrated Discovery (DAVID) and Panther Classification System. Briefly, a list of 769 anlotinib-responsive genes was uploaded to DAVID bioinformatics resources 6.7 and performed Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway , and a list of 127 genes was uploaded to PANTHER Classification System and performed Panther Pathway analysis .
Wound healing scratch assay
105 NCI-H1975 cells were seeded on 6-well plates for 24 h, and then were starved for 24 h. Scratch wound was performed using 200 μL pipet tip. Replace the medium with fresh 90% RPMI 1640 medium (Gibco, USA) and 10% FBS (Gibco, USA). Meanwhile, other wells were treated with anlotinib (4 μg/ml), CXCL2 (50 ng/ml, Pepro Tech, USA), alone or together. Phase-contrast microscope (Nikon, Japan) was performed to capture images. The migration rate was calculated based on the change of wound width.
Cell invasion assay
Matrigel matrix (1:8 dilution, Corning, USA) was coated on transwell membrane. NCI-H1975 cells were seeded onto the top precoated chamber (5 × 104 cells per well for 24 h evaluation; 2 × 104 cells per well for 48 h evaluation) in 100 μL of FBS-free medium containing anlotinib (2 μg/ml) and CXCL2 (100 ng/ml, Pepro Tech, USA), alone or together. The medium containing 15% FBS (Gibco, USA) was placed in the bottom chamber. After 24 h or 48 h incubation, the invasive cells were fixed in 3.7% paraformaldehyde and stained with 0.1% crystal violet. Pictures were captured using fluorescence microscopy (Nikon, Japan). Cell numbers were examined by use of the microscopy affiliated software.
Cell apoptosis assay
Cell apoptosis detection was performed as previous described . Annexin V-FITC/PI apoptosis kit (Zoman Biotechnology Co., Ltd., China) was used to examine the cell apoptosis. NCI-H1975 cells were exposed to CXCL2 (100 ng/ml, Pepro Tech, USA) and anlotinib (4 μg/ml), alone or together for 24 h, and then stained with Annexin V-FITC and PI simultaneously. Flow cytometry (BD LSRFortessa, USA) was used for detecting apoptotic cells. PI-positive cells were designated end-stage apoptotic cells, and FITC-positive cells were designated early-stage apoptotic cells.
There are at least three biological replicates, excluding RNA-seq, for each sample. GraphPad Prism 5 was use for histogram and statistical analysis. Student’s t-test was used to examine the raw data. Differences were considered significant at *P < 0.05, **P < 0.01 and ***P < 0.001.
Anlotinib-induced cytotoxicity attenuates in anlotinib resistant NCI-H1975 cells
Identification of anlotinib-responsive genes in NCI-H1975 cells
Identification of genes associated with anlotinib resistance in anlotinib resistant NCI-H1975 cells
CXCL2 is involved in the resistance in anlotinib resistant NCI-H1975 cells
Our previous studies have shown that anlotinib is an effective anti-tumor agent for NSCLC at 3rd line [9, 10, 11, 35]. It is also demonstrated that anlotinib selectively inhibits VEGFR (2/3), FGFR (1–4), and PDGFR (α/β) [7, 8]. However, drug resistance is inevitable in the last stage of cancer therapy.
NSCLC patients harboring EGFR (L858R and 19 Del) mutation received great benefit in more than 10 years ago, due to the finding of Gefitinib . Although the first generation TKIs (Gefitinib, Erlotinib and Icotinib) have demonstrated its efficacy upon those NSCLC patients, acquired resistance will occurs after a median about 10 months therapy [12, 13, 14, 15]. Subsequently, the scientists focused on the resistant mechanism study, and found that T790 M mutation, MET amplification, HER-2 mutation, and other gene alteration are contributed to acquired resistance [12, 16, 17]. Because of the patients harboring T790 M accounts for about 50% of the acquired resistance, scientists next screened out AZD9291, and brought greatly benefit for those patients with T790 M mutation [18, 19, 20].
In recent years, the high-throughput sequencing technology has served as an important platform to characterize the acquired resistance . Understanding the underlying anlotinib resistant mechanism will benefit the therapeutic outcome. To address this issue, in the present study we performed transcriptome profiling analysis in NCI-H1975 cells, anlotinib resistant NCI-H1975 cells, and their anlotinib-treated cells. We identified a set of 127 genes that are potentially associated with anlotinib resistance via transcriptome profiling analysis (Fig. 3b).
Among these 127 candidate genes CXCL2 raised our attention. CXCL2 is an important cytokine, which usually is involved in wound healing, cancer metastasis, apoptosis, and angiogenesis [33, 34, 38]. Recent studies revealed CXCL2 is also associated with acquired resistance in breast cancer, colorectal cancer and glioblastoma [30, 31, 32]. These phenomena gave us a hint that whether CXCL2 plays an important role in anlotinib resistance. To address this issue, we performed function assays to examine the relevance between CXCL2 and anlotinib resistance. As we expected, our results showed that anlotinib-induced apoptosis and the inhibition of migration and invasion in NCI-H1975 cells were significantly recovered when supplementing exogenous CXCL2, suggesting an important link between CXCL2 and anlotinib resistance.
In brief, our findings revealed a novel resistant mechanism of anlotinib and provided a basis for circumventing anlotinib resistance.
The authors would like to thank Dr. Jun Wu for assistance of bioinformatic analysis and analysis, thank Dr. Xunqiang Wang for providing anlotinib.
Publication of this article was supported by the program of system biomedicine innovation center from Shanghai Jiao Tong University (Project No. 15ZH4009); the key program of translational medicine from Shanghai Jiao Tong University School of Medicine (Project No. 15ZH1008); National Natural Science Foundation of China (Project No. 81673015); and the project of Science and Technology Commission of Shanghai Municipality (Project No. 16140902700).
Availability of data and materials
The profiling datasets of this article are available in the EMBL database under accession number E-MTAB-5997 and E-MTAB-7068. Other data including anlotinib resistant NCI-H1975 cell line are available based on reasonable request.
About this supplement
This article has been published as part of BMC Medical Genomics Volume 12 Supplement 2, 2019: Selected articles from BGRS\SB-2018: medical genomics. The full contents of the supplement are available online at https://bmcmedgenomics.biomedcentral.com/articles/supplements/volume-12-supplement-2.
Experiments were conceived and designed by BH, XZ and JL. Cell assays were performed by JL, JQ, BZ, SW, RQ, MH and YZ. RNA-seq library was performed by WX and LZ. Bioinformatics analysis and statistical analysis were performed by LZ and JL. The manuscript was written by JL, and revised by XZ and BH. All of the authors have read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 1.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.Google Scholar
- 2.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. 2018;68(1):7–30.Google Scholar
- 3.Lu J, Han BH. Liquid biopsy promotes non-small cell Lung Cancer precision therapy. Technol Cancer Res T. 2018;7(17):1–7.Google Scholar
- 4.Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non–small cell Lung Cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Net. 2017;15(4):504–35.Google Scholar
- 5.Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, et al. NCCN guidelines insights: non-small cell Lung Cancer, version 4.2016. J Natl Compr Canc Net. 2016;14(3):255–64.Google Scholar
- 9.Han BH, Li K, Zhao YZ, Li BL, Cheng Y, Zhou JY, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018. https://doi.org/10.1038/bjc.2017.478.
- 10.Han BH, Li K, Wang QM, Zhao YZ, Zhang L, Shi JH, et al. Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2017;18:S3.Google Scholar
- 11.Han BH, Li K, Wang QM, Zhang L, Shi JH, Wang ZH, Cheng Y, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018. https://doi.org/10.1001/jamaoncol.2018.3039.
- 13.Gerber NK, Yamada Y, Rimner A, Shi WJ, Riely GJ, Beal K, et al. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant Lung adenocarcinoma. Int J Radiat Oncol. 2014;89(2):322–9.Google Scholar
- 18.Parra HJS, Noto L, Galetta D, Ferrau F, Gebbia V, Tassone P, et al. A phase II, noncomparative, open label, multicentre, study of AZD9291 in patients with locally advanced or metastatic EGFR mutated “T790M undetectable or unknown” non-small cell lung cancer (stage IIB-IV) after no immediate prior EGFR TKI (OSIRIS study). J Clin Oncol. 2017;35(15_suppl):TPS9107.Google Scholar
- 19.Ku BM, Bae YH, Koh J, Sun JM, Lee SH, Ahn JS, et al. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR (L858R/T790M) in non-small cell lung cancer cells. Invest New Drug. 2016;34(4):407–15.Google Scholar
- 25.Lu J, Chen J, Kang Y, Wu J, Shi H, Fu Y, et al. Jinfukang induces cellular apoptosis through activation of Fas and DR4 in A549 cells. Oncol Lett. 2018. https://doi.org/10.3892/ol.2018.9149.
- 27.Lu J, Zhang X, Shen T, Ma C, Wu J, Kong H, et al. Epigenetic profiling of H3K4Me3 reveals herbal medicine Jinfukang-induced epigenetic alteration is involved in anti-Lung Cancer activity. Evid Based Complement Alternat Med. 2016. https://doi.org/10.1155/2016/7276161.
- 32.De Porras VR, Bystrup S, Martínez-Cardús A, Pluvinet R, Sumoy L, Howells L, et al. Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-chemokine/NF-κB signalling pathway. Sci Rep. 2016;6:24675.Google Scholar
- 35.Lu J, Zhong H, Chu T, Zhang XY, Li R, Sun JY, et al. Role of anlotinib-induced CCL2 decrease in antiangiogenesis and response prediction for non-small cell lung cancer therapy. Eur Respir J. 2018. https://doi.org/10.1183/13993003.01562-2018
- 37.Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–50.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.